MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes

A new study led by Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute, found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.

The results of the STEP-HFpEF DM trial were presented at the American College of Cardiology Scientific Session and published in the New England Journal of Medicine.

See some of the national media coverage on the study's findings below.

• CNN: Weight-Loss Drug Wegovy Offers Benefits for People with Diabetes and Common Form of Heart Failure, Study Finds
• Good Morning America: New Report on the Effect of Weight Loss Drugs on Heart Disease
• U.S. News & World Report: Wegovy Helps Those With Both Diabetes, Heart Failure: Study
• Healio: Wegovy improves symptoms, physical function for obesity-related heart failure with diabetes
• TCTMD: STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed | tctmd.com
• Cardiovascular Business: Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes
• Medscape: Semaglutide Beneficial in HFpEF Patients With Diabetes
• HCP Live: STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
• Medpage Today: Wegovy Helps HFpEF Patients With Diabetes Mellitus
• Market Watch: Wegovy’s Heart Benefits are not Just Linked with Weight Loss, New Study Suggests
• Medical Xpress: Study Suggests Wegovy Helps Those With Both Diabetes, Heart Failure
• Patient Care: Semaglutide 2.4mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
• Physician's Weekly: ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes